Cancer clinical trials in the region Auvergne-Rhône-Alpes

498 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07059845 #2025-521606-18-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT07059845 #2025-521606-18-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required FIGO stages
Stage III Stage IV
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
13 recruiting sites
Abbvie
Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) Multiple myeloma #NCT04935684
Required histologic types
B cell lymphoma T cell lymphoma Hodgkin lymphoma CLL (Chronic Lymphocytic Leukemia) Symptomatic multiple myeloma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CHU de Clermont-Ferrand
Phase 2 Multiple myeloma #NCT05572229 #2022-001594-31
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
17 recruiting sites
Hôpital universitaire de Lille
Phase 2 Lung cancer #NCT06855771 #2024-519814-29-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Bristol-Myers Squibb
Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06682988 #2024-517184-23-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required folate alpha receptor score
Greater than or equal to 75%
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
8 recruiting sites
Abbvie
Phase 2 Thyroid and adrenal gland cancer #NCT03732495
Required histologic types
Thyroid cancer
Required histologic sub types
Differentiated carcinoma Poorly differentiated carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Radioactive iodine
Required radioactive iodine status
Resistant to radioactive iodine
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
14 recruiting sites
Centre Léon Bérard
Phase 2 Lung cancer #NCT04613596 #2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 2 Breast cancer #NCT07405801 #2025-523013-28-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
PIK3CA
4 recruiting sites
Hoffmann-La Roche
Phase 2 Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Sarcoma and GIST Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic types
Stomach Oesogastric junction Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma Ampullary carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Negative (< 1) CPS Positive (1 <= X < 5)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
7 recruiting sites
UNICANCER